Equities Analysts Offer Predictions for EW FY2025 Earnings

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Investment analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for Edwards Lifesciences in a report issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.44 per share for the year, up from their prior forecast of $2.43. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.56 per share.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences's quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the business earned $0.59 earnings per share.

Several other equities research analysts have also issued reports on the stock. Sanford C. Bernstein raised shares of Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a research note on Monday, October 28th. Evercore ISI lowered their price target on Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating on the stock in a research report on Tuesday, October 1st. Piper Sandler cut their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Robert W. Baird decreased their target price on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. Finally, Stifel Nicolaus boosted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock a "hold" rating in a report on Thursday, December 5th. Sixteen investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $79.40.

Edwards Lifesciences Stock Performance

EW stock traded up $0.52 during midday trading on Thursday, hitting $74.16. 3,446,932 shares of the stock traded hands, compared to its average volume of 4,037,682. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock's fifty day simple moving average is $71.52 and its 200-day simple moving average is $72.31. The firm has a market cap of $43.74 billion, a P/E ratio of 10.70, a PEG ratio of 3.61 and a beta of 1.12.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company's stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,500 shares of company stock valued at $2,508,350. 1.29% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in EW. FSA Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at $30,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC boosted its stake in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after buying an additional 308 shares during the period. Peoples Bank KS acquired a new position in shares of Edwards Lifesciences during the third quarter worth about $40,000. Finally, JFS Wealth Advisors LLC increased its stake in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock worth $46,000 after buying an additional 166 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.